EUCTR2019-000655-14-IT进行中（未招募）1 期
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older - n.a.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,539
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Sixty years of age and older on the day of inclusion
- •- Able to attend all scheduled visits and to comply with all trial procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 770
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 770
排除标准
- •- Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile
- •- Participation at the time of study enrollment (or in the 4 weeks [28 days] preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- •- Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to V02
- •- Previous vaccination against influenza (in the previous 6 months) with either the trial vaccine or another vaccine
- •- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- •- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
- •- Thrombocytopenia or bleeding disorder, contraindicating intramuscular (IM) vaccination based on Investigator’s judgement
- •- Alcohol or substance abuse that, in the opinion of the Investigator might interfere with the trial conduct or completion
- •- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
- •- Moderate or severe acute illness/infection (according to Investigator judgment) or febrile illness (temperature >/= 38.0°C) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
- •- Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
- •- Personal or family history of Guillain Barré syndrome (GBS)
- •- Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy and participants who have a history of neoplastic disease and have been disease free for >/= 5 years)
研究者
相似试验
进行中（未招募）
1 期
Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and OlderEUCTR2019-000655-14-BESanofi Pasteur1,540
已完成
3 期
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and OlderFlu10047438InfluenzaNL-OMON48124Sanofi-aventis340
进行中（未招募）
1 期
Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and OlderPrevention of influenza infection in adults from 60 years of age and olderMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-000655-14-DESanofi Pasteur1,540
进行中（未招募）
1 期
Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and OlderPrevention of influenza infection in adults from 60 years of age and olderMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-000655-14-FRSanofi Pasteur1,540
进行中（未招募）
1 期
Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and OlderPrevention of influenza infection in adults from 60 years of age and olderMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-000655-14-NLSanofi Pasteur1,539